Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
TORONTO, December 10, 2024 BUSINESS WIRE Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (" Cybin " or the " Company "), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology ("ACNP") Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona. The data presented include 12-month efficacy results from the Company's Phase 2 study of CYB003, its deuterated psilocin program, in Major Depressive Disorder ("MDD"), which showed durable response and remission rates at 12 months, in addition to results from a completed Phase 1b study exploring drug-drug interactions between N,N-dimethyltryptamine ("DMT") and selective serotonin reuptake inhibitors ("SSRIs"), in MDD patients. "The ACNP annual meeting is an excellent opportunity to share the rapid clinical progress Cybin
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy ResultsBusiness Wire
- Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline [Yahoo! Finance]Yahoo! Finance
- Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024Business Wire
- Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.MarketBeat
- Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder [Yahoo! Finance]Yahoo! Finance
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 1/8/25 - Form F-X
- 1/8/25 - Form F-10
- 12/10/24 - Form 6-K
- CYBN's page on the SEC website